logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Pharmacopeia Drug Discovery, Inc.


USPTO Granted Patents = 52



Forward Citations = 339

Loading Chart...
Loading Chart...

221 inventors (with patents filed for the assignee):

goldMedal John J Baldwin (19 out of 229 patents)

silverMedal Michael P Dwyer (11 out of 52 patents)

bronzeMedal Tao Guo (11 out of 48 patents)

4.  Douglas Walsh Hobbs (10 out of 25 patents)

5.  Kurt William Saionz (8 out of 19 patents)

6.  Vinh D Tran (8 out of 16 patents)

7.  Michael H J Ohlmeyer (8 out of 15 patents)

8.  Andrew William Stamford (8 out of 125 patents)

9.  Roland Ellwood Dolle (8 out of 81 patents)

10.  Vidyadhar Madhav Paradkar (8 out of 28 patents)

11.  Ge Li (7 out of 82 patents)

12.  Lawrence Wayne Dillard (7 out of 64 patents)

13.  Suresh D Babu (7 out of 26 patents)

14.  Gonghua Pan (7 out of 11 patents)

15.  Shawn David Erickson (7 out of 40 patents)


Core Competencies:
BACE-1 Inhibitors
Aspartyl Protease Inhibitors
CXCR3 Antagonists
Adrenoreceptor Agonists
CXC-Chemokine Receptor Ligands
Cyclin Dependent Kinase Inhibitors
IL-8 Receptor Antagonists
NOS Inhibitors
Piperazine Compounds
Fluorescent Capture Assay
Combinatorial Synthesis
Fluid Control Technologies

52 patents:

1. 9062007 - Cyclic amide BACE-1 inhibitors having a benzamide substituent (2015-06-23),
2. 8937093 - Heterocyclic aspartyl protease inhibitors (2015-01-20),
3. 8778980 - Heterocyclic aspartyl protease inhibitors (2014-07-15),
4. 8722708 - Substituted isoindolines as aspartyl protease inhibitors (2014-05-13),
5. 8691831 - Heterocyclic aspartyl protease inhibitors (2014-04-08),
6. 8623867 - Cyclic amine BACE-1 inhibitors having a benzamide substituent (2014-01-07),
7. 8242112 - Heterocyclic aspartyl protease inhibitors (2012-08-14),
8. 8207170 - Heterocyclic substituted piperazines with CXCR3 antagonist activity (2012-06-26),
9. 8178513 - Heterocyclic aspartyl protease inhibitors (2012-05-15),
10. 7985748 - ALPHA2C adrenoreceptor agonists (2011-07-26),
11. 7964646 - 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands (2011-06-21),
12. 7947720 - 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands (2011-05-24),
13. 7879838 - Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity (2011-02-01),
14. 7868006 - Heterocyclic substituted piperazines with CXCR3 antagonist activity (2011-01-11),
15. 7799789 - Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity (2010-09-21),
Pharmacopeia Drug Discovery is a leading pharmaceutical research and development company. With a focus on innovative drug discovery, we strive to bring new treatments to patients worldwide. Our team of experienced scientists and researchers utilize cutting-edge technologies and advanced methodologies to accelerate the drug discovery process. Collaborating with pharmaceutical partners, we aim to address unmet medical needs and improve healthcare outcomes. Visit our website for more information.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

52 Patents

#26 in Princeton, NJ

#273 in New Jersey

#6,537 in US

#13,143 in the World

...
Princeton, NJ, United States of America

Pharmacopeia Drug Discovery, Inc.

Forward Citations = 339

221 inventors:

goldMedal John J Baldwin (19 out of 229 patents)

silverMedal Michael P Dwyer (11 out of 52 patents)

bronzeMedal Tao Guo (11 out of 48 patents)

4.  Douglas Walsh Hobbs (10 out of 25 patents)

5.  Kurt William Saionz (8 out of 19 patents)

Please report any incorrect information to support@idiyas.com
Loading…